Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 11/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacemazine SCHEMBL29546195 | 1.00 | BCHE (0.63) | BCHEPOLBATMACHENOX1 | |
| SCHEMBL7351545 | 0.86 | BCHE (0.59) | BCHEPOLBATMACHENOX1 | |
| SCHEMBL7350072 | 0.84 | BCHE (0.63) | BCHEPOLBATMACHENOX1 | |
| SCHEMBL627575 | 0.81 | BCHE (0.65) | BCHEPOLBATMACHENOX1 | |
| SCHEMBL7982855 | 0.78 | BCHE (0.67) | BCHEPOLBATMACHENOX1 | |
| SCHEMBL4759685 | 0.77 | BCHE (0.65) | BCHEACHENOX1ADRB3HRH2 | |
| SCHEMBL4759501 | 0.77 | BCHE (0.65) | BCHEACHENOX1ADRB3HRH2 | |
| SCHEMBL2681239 | 0.77 | BCHE (0.70) | BCHEACHENOX1ADRB3HRH2 | |
| Fumaric Acid SCHEMBL7345354 | 0.77 | ALDH1A1 (0.45) | BCHEPOLBATMACHEADRB3 | |
| SCHEMBL7343904 | 0.77 | BCHE (1.00) | BCHEPOLBATMACHENOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | UNIVERSITÉ COTE D'AZUR (FR) | 2024-02-15 | — | — | US | claimed |
| EP-4255437-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | Centre National de la Recherche Scientifique (FR) | 2023-10-11 | — | — | EP | claimed |
| WO-2022122688-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| US-20110212173-A1 | Controlled Release Treatment of Depression | e-Therapeutics Ple (GB) | 2011-09-01 | — | — | US | claimed |
| EP-2315585-A1 | CONTROLLED RELEASE TREATMENT OF DEPRESSION | E-Therapeutics plc (GB) | 2011-05-04 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101801361-A | Treatment of depression | THERAPEUTICS LTD E | 2010-08-11 | — | — | CN | claimed |
| WO-2010004256-A1 | CONTROLLED RELEASE TREATMENT OF DEPRESSION | E-THERAPEUTICS PLC (GB) | 2010-01-14 | — | — | WO | claimed |
| US-20090005443-A1 | Treatment of Depression | E-THERAPEUTICS LIMITED (GB) | 2009-01-01 | — | — | US | claimed |
| WO-2009001040-A2 | TREATMENT OF DEPRESSION | E-THERAPEUTICS PLC (GB) | 2008-12-31 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | GRIK5, HTR5A, CYP3A5 | BCHE 689/4885POLB 4383/4885ATM 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.